Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q3 2024 · 10-Q
Revenue$10.64B$10.64B+4.9% vs Q3 2023 Net Income$1.65B$1.65B+14.6% vs Q3 2023 EPS Diluted$0.94$0.94+14.6% vs Q3 2023 Operating Income$1,859,000,000+12.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,149,000,000+63.2% Margins · derivedOperating margin17.5%+1.2 pt vs Q3 2023
Net margin15.5%+1.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Oct 31, 2024 · 31 d after period end